Fusion Antibodies plc is a United Kingdom-based collaborative research organization (CRO) company. The Company offers an integrated end-to-end range of antibody discovery, engineering and expression services for all stages of human therapeutic, veterinary therapeutic and diagnostic antibody development. It offers a range of services including antibody discovery/generation, development, characterization, optimization, and small-scale production. In addition, the Company also offers antigen design, antigen expression, antibody purification and sequencing, antibody humanization using Fusion's proprietary CDRx platform and cell line development, producing antibody generating stable cell lines optimized for downstream use by the customer to produce material for clinical trials. Its Integrated Therapeutic Antibody Services (ITA) offering enhances the efficiency of this process by providing a continuous service offering from as early as target nomination to as far as a stable cell line.
Company Information
About this company
Key people
Adrian Kinkaid
Chief Executive Officer, Executive Director
Stephen Smyth
Interim Chief Financial Officer and Company Secretary, Executive Director
Richard Buick
Chief Scientific Officer, Executive Director
Simon Douglas
Non-Executive Chairman of the Board
Colin J. Walsh
Non-Executive Director
Matthew Paul Baker
Non-Executive Independent Director
Click to see more
Key facts
- Shares in issue113.66m
- EPICFAB
- ISINGB00BDQZGK16
- LocationUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap£16.48m
- Employees24
- ExchangeLondon Stock Exchange (LON)
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.